Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study is being undertaken to investigate the efficacy and safety of Juvista (given as an
intradermal injection of 200ng/100µl per linear centimetre of wound margin) in the prevention
or improvement of scar appearance when administered intradermally to approximated wound
margins following surgical scar revision.
In addition, this study will compare the scar revision techniques of complete excision
(excision of the entire scar during one surgical procedure) and staged excision (excision of
the outmost segments and central core separately).